Skip Navigation
Patent
LIVER CANCER-SPECIFIC BIOMARKER (KR 10-2180117)
肝癌特异性生物标志物 (CN ZL201980053149.7)
COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER COMPRISING BANF1, PLOD3 OR SF3B4 INHIBITOR AS ACTIVE INGREDIENT (KR 10-2270926)
LIVER CANCER-SPECIFIC BIOMARKERS AND USE THEREOF (KR 10-2023-0064729)
COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING A GAS5 INHIBITOR AS AN ACTIVE INGREDIENT (KR 10-2022-0063617)
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER COMPRISING A GAS5 AND SMARCA4 INHIBITOR AS AN ACTIVE INGREDIENT (KR 10-2930473)
COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING AN MSH2 INHIBITOR AS AN ACTIVE INGREDIENT (KR 10-2022-0070947)
COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING AN MSH6 INHIBITOR AS AN ACTIVE INGREDIENT (KR 10-2022-0070948)
COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING MSH2 OR MSH6 INHIBITOR AS ACTIVE INGREDIENT (US 18682165)
COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING MSH2 OR MSH6 INHIBITOR AS ACTIVE INGREDIENT (EU 22856165.0)
包含MSH2或MSH6抑制剂作为有效成分的用于预防或治疗癌症的组合物 (CN 202280054930.8)
MSH2またはMSH6抑制剤を有効成分として含む癌予防または治療用組成物 (JP 2024-508093)
COMPOSITION FOR THE PREVENTION OR TREATMENT OF LIVER CANCER (KR 10-2344598)
COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER, COMPRISING TSP1 AS AN ACTIVE INGREDIENT (KR 10-2576855)
COMPOSITION FOR THE PREVENTION OR TREATMENT OF LIVER CANCER COMPRISING MODIFIED RT-LET7 AS AN ACTIVE INGREDIENT (KR 10-2329524)
DELIVERY SYSTEM FOR THE PREVENTION OR TREATMENT OF LIVER CANCER INCLUDING MODIFIED RT-LET7 AS AN ACTIVE INGREDIENT (KR 10-2428121)
DELIVERY SYSTEM FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING MODIFIED RT-LET7 AS AN ACTIVE INGREDIENT (KR 10-2771160)
COMPOSITION FOR PREVENTION OR TREATMENT OF LIVER CANCER, COMPRISING MODIFIED RT-LET7 AS ACTIVE INGREDIENT (US 18681745)
COMPOSITION FOR PREVENTION OR TREATMENT OF LIVER CANCER, COMPRISING MODIFIED RT-LET7 AS ACTIVE INGREDIENT (EU 22853368.3)
包含修饰的RT-LET7作为有效成分的用于预防或治疗肝癌的组合物 (CN 202280054494.4)
変形されたRT-LET7を有効成分として含む肝癌の予防または治療用組成物 (JP 7766375)
COMPOSITION FOR PREVENTION OR TREATMENT OF LIVER CANCER, COMPRISING MODIFIED RT-LET7 AS ACTIVE INGREDIENT (CA 3228077)
COMPOSITION FOR PREVENTION OR TREATMENT OF LIVER CANCER, COMPRISING MODIFIED RT-LET7 AS ACTIVE INGREDIENT (AU 2022324176)
GKN1(GASTROKINE 1) SPECIFIC ANTIBODY AND USE THEREOF (KR 10-2590757)
GASTROKINE 1 SPECIFIC ANTIBODY AND USE THEREOF (KR 10-2022-0140869)
COMPOUND COMPRISING A MODIFIED MIRNA INHIBITING LET-7I-5P EXPRESSION CONJUGATED WITH A HEPATOCYTE-TARGETING MOIETY FOR THE PREVENTION OR TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS AND LIVER FIBROSIS (KR 10-2026-0042454)
Publication
2025
Oncogenic function of growth arrest-specific transcript 5 by competing with miR-423-3p to regulate SMARCA4 in hepatocellular carcinoma
Sang Yean Kim, Jin Woong Ha, Min Jeong Na, Soyoung Jeon, Jung Hwan Yoon, Won Sang Park, Suk Woo Nam
Exp. Mol. Med. 02 June 2025
doi: 10.1038/s12276-025-01459-4
2024
The roles and mechanisms of coding and noncoding RNA variations in cancer
Sang Yean Kim, Min Jeong Na, Sungpil Yoon, Eunbi Shin, Jin Woong Ha, Soyoung Jeon and Suk Woo Nam
Exp. Mol. Med., 02 September 2024 | https://doi.org/10.1038/s12276-024-01307-x
2023
ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer.
Kim HS, Na MJ, Son KH, Yang HD, Kim SY, Shin E, Ha JW, Jeon S, Kang K, Moon K, Park WS, Nam SW.
Exp. Mol. Med., Published: 04 January 2023 | https://doi.org/10.1038/s12276-022-00916-8
2022
Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma.
Eun JW, Jang JW, Yang HD, Kim J, Kim SY, Na MJ, Shin E, Ha JW, Jeon S, Ahn YM, Park WS, Nam SW.
J Clin Med. 2022 Apr 11;11(8):2128. doi: 10.3390/jcm11082128.
2022
hnRNPC induces isoform shifts in miR-21-5p leading to cancer development.
Park S, Yang HD, Seo JW, Nam JW, Nam SW.
Exp Mol Med. 2022 Jun;54(6):812-824. doi: 10.1038/s12276-022-00792-2. Epub 2022 Jun 21.
2021
SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer.
Kim SY, Shen Q, Son K, Kim HS, Yang HD, Na MJ, Shin E, Yu S, Kang K, You JS, Yu KR, Jeong SM, Lee EK, Ahn YM, Park WS, Nam SW.
Oncogene. 2021 Jul;40(28):4652-4662. doi: 10.1038/s41388-021-01875-6. Epub 2021 Jun 17.PMID: 341406
더보기